A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy

Journal of Veterinary Internal Medicine

Volumn 16, Issue 3, 2002, Pages 255-261

  Fuentes, Virginia Luis ^a,c   Corcoran, Brendan ^a   French, Anne ^a   Schober, Karsten E ^a   Kleemann, Rainer ^b   Justus, Claus ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Calcium sensitizing agent; Congestive cardiac failure; Doberman Pinscher; English Cocker Spaniel; Heart; Inodilator

Indexed keywords

CARDIOTONIC AGENT; PIMOBENDAN; PYRIDAZINE DERIVATIVE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; DOUBLE BLIND PROCEDURE; FEMALE; MALE; PATHOLOGY; PEDIGREE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

ANIMALS; CARDIOMYOPATHY, DILATED; CARDIOTONIC AGENTS; DOG DISEASES; DOGS; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, CONGESTIVE; MALE; PEDIGREE; PROGNOSIS; PYRIDAZINES; SURVIVAL; TREATMENT OUTCOME;

EID: 0036581696     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2002.tb02366.x     Document Type: Article

References (68)

1. Fitton A, Brogden RN. Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure. Drugs Aging 1994;4:417-441.
2. Mathew L, Katz SD. Calcium sensitising agents in heart failure. Drugs Aging 1998;12:191-204.
3. Holubarsch C. New inotropic concepts: Rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors. Cardiology 1997;88(Suppl 2):12-20.
4. Solaro RJ, Fujino K, Sperelakis N. The positive inotropic effect of pimobendan involves stereospecific increases in the calcium sensitivity of cardiac myofilaments. J Cardiovasc Pharmacol 1989; 14(Suppl 2):S7-S12.
5. 2+ binding. J Mol Cell Cardiol 1996;2g:1375-1383.
6. Hasenfuss G, Holubarsch C, Just H, et al. Energetic aspects of inotropic interventions in rat myocardium. Basic Res Cardiol 1987; 82(Suppl 2):251-259.
7. Holubarsch CH, Hasenfuss G, Just H, et al. Modulation of myothermal economy of isometric force generation by positive inotropic interventions in the guinea pig myocardium. Cardioscience 1990; 1:33-41.
8. Holubarsch C, Hasenfuss G. Just H, et al. Influence of the positive inotropic substance pimobendan (UD-CG 115 BS) on contractile economy of guinea pig papillary muscles. J Cardiovasc Pharmacol 1989;14(Suppl 2):S13-S17.
9. Goto Y, Hata K. Mechanoenergetic effect of pimobendan in failing dog hearts. Heart Vessels 1997;12(Supp]j:103-105.
10. 2+ activation and the inotropic effect of pimobendan: Comparison with milrinone. Circ Res 1988;63: 911-922.
11. Hasenfuss G, Holubarsch C, Heiss HW, et al. Influence of the calcium-sensitizer UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. Comparison with nitroprusside. Basic Res Cardiol 1989;84(Suppl 1):225-233.
12. Remme WJ, Wiesfeld AC, Look MP. et al. Hemodynamic effects of intravenous pimobendan in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 1989;14(Suppl 2):S41-S44.
13. Asanoi H, Ishizaka S, Kameyama T, et al. Disparate inotropic and lusitropic responses to pimobendan in conscious dogs with tachycardia-induced heart failure. J Cardiovasc Pharmacol 1994;23:268-274.
14. Ohte N, Cheng CP, Suzuki M, et al. The cardiac effects of pimobendan (but not amrinone) are preserved at rest and during exercise in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther 1997;282:23-31
15. Ishiki R, Ishihara T, Izawa H, et al. Acute effects of a single low oral dose of pimobendan on left ventricular systolic and diastolic function in patients with congestive heart failure. J Cardiovasc Pharmacol 2000;35:897-905.
16. Ichihara K, Abiko Y. The effect of pimobendan on myocardial mechanical function and metabolism in dogs: Comparison with dobutamme. J Pharm Pharmacol 1991;43:583-588.
17. Hata K, Goto Y, Futaki S, et al. Mechanoenergetic effects of pimobendan in canine left ventricles. Comparison with dobutamine. Circulation 1992;86:1291-1301.
18. Meel JC, Diederen W. Hemodynamic profile of the cardiotonic agent pimobendan. J Cardiovasc Pharmacol 1989;14(Suppl 2):S1-S6.
19. Pouleur H, Hanet C, Schroder E, et al. Effects of pimobendan (UD-CG 115 BS) on left ventricular inotropic state in conscious dogs and in patients with heart failure. J Cardiovasc Pharmacol 1989; 14(Suppl 2):S18-S22.
20. Bohm M, Flesch M, Schnabel P. Role of G-proteins in altered beta-adrenergic responsiveness in the failing and hypertrophied myocardium. Basic Res Cardiol 1996;91(Suppl 2):47-51.
21. Akhter SA, Eckhart AD, Rockman HA, et al. In vivo inhibition of elevated myocardial beta-adrenergic receptor kinase activity in hybrid transgenic mice restores normal beta-adrenergic signaling and function. Circulation 1999;100:648-653.
22. Sato N, Asai K, Okumura S, et al. Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure. Am J Physiol 1999;276:H1699-H1705.
23. Ravens U, Himmel HM, Fluss M, et al. Phosphodiesterase inhibition and Ca2- sensitization. Mol Cell Biochem 1996;157:245-249.
24. Verdouw PD, Hartog JM, Duncker DJ, et al. Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties. Eur J Pharmacol 1986;126:21-30.
25. Fujimoto S, Matsuda T. Effects of pimobendan, a cardiotonic and vasodilating agent with phosphodiesterase inhibiting properties, on isolated arteries and veins of rats. J Pharmacol Exp Ther 1990;252: 1304-1311.
26. Erlemeier HH, Kupper W, Bleifeld W. Comparison of hormonal and haemodynamic changes after long-term oral therapy with pimobendan or enalapril - A double-blind randomized study. Eur Heart J 1991;12:889-899.
27. Katz SD, Kubo SH, Jessup M. et al. A multicenter. randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure. Am Heart J 1992;123:95-103.
28. Renard M, Walter M, Liebens I. et al. Pimobendane (UD-CG 115 BS) in chronic congestive heart failure. Short-term and one-month effects of a new inotropic vasodilating agent. Chest 1988;93:1159-1164.
29. Hagemeijer F, Brand HJ, Mechelen R. Hemodynarmic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1989;63: 571-576.
30. Hagemeijer F. Roth W, Brand HJ Correlations between the cardiovascular effects of pimobendan and plasma concentrations of the parent compound and of its major active metabolite, UD-CG 212 CL, in patients with congestive heart failure. J Cardiovasc Pharmacol 1989; 14(Suppl 2):S57-S64.
31. Walter M, Liebens I, Goethals H, et al. Pimobendane (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic cross-over and double-blind study with two different doses. Br J Clin Pliarmacol 1988;25:323-329.
32. Kubo SH, Gollub S, Bourge R, et al. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group. Circulation 1992;85;942-949.
33. Sasayama S, Asanoi H, Kihara Y, et al. Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure. Heart Vessels 1994;9:113-120.
34. Remme WJ, Krayenbuhl HP, Baumann G, et al. Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group. Eur Heart J 1994;15:947-956.
35. Lubsen J, Just H, Hjalmarsson AC, et al. Effect of pimobendan on exercise capacity in patients with heart failure: Main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996; 76.223-231.
36. Massie B, Bourassa M, DiBianco R, et al. Long-term oral administration of amrinone for congestive heart failure: Lack of efficacy in a multicenter controlled trial. Circulation 1985;71:963-971.
37. Uretsky BF, Jessup M, Konstam MA, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation 1990; 82:774-780.
38. Kato K. Clinical efficacy and safety of pimobendan in treatment of heart failure - Experience in Japan. Cardiology 1997;88(Suppl 2): 28-36.
39. Hauf GF, Grom E, Jahnchen E, et al. Acute and long-term hemodynamic effects of pimobendan (UD-CG 115 BS) in comparison with captopnl. J Cardiovasc Pharmacol 1989:14(Suppl 2):S49-S56.
40. Yoshikawa T, Baba A, Suzuki M, et al. Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. For the Keio Interhospital Cardiology Study (KICS) Group. Am J Cardiol 2000;85:1495-1497.
41. Sisson D, Thomas WP. Myocardial diseases. In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine. Diseases of the Dog and Cat. Philadelphia, PA: WB Saunders; 1995:995-1033
42. Calvert CA, Chapman WC, Toal RC. Congestive cardiomyopathy in Doberman Pinscher dogs. J Am Vet Med Assoc 1982;181: 598-602.
43. Calvert CA, Pickus CW, Jacobs GJ, et al. Signalment, survival, and prognostic factors in Doberman Pinschers with end-stage cardiomyopathy. J Vet Intern Med 1997;11:323-326.
44. Thomas RE. Congestive cardiac failure in young Cocker Spaniels (a form of cardioinyopathy?); Details of eight cases. J Small Anim Pract 1987,28:265-279.
45. Staaden RV. Cardiomyopathy of English Cocker Spaniels. J Am Vet Med Assoc 1981;178:1289-1292.
46. Kittleson MD, Eyster GE, Knowlen GG, et al. Myocardial function in small dogs with chronic mitral regurgitation and severe congestive heart failure. J Am Vet Med Assoc 1984;184:455-459.
47. Borow KM, Green LH, Mann T, et al. End-systolic volume as a predictor of postoperative left ventricular performance in volume overload from valvular regurgitation. Am J Med 1980;68:655-663.
48. Tidholm A, Svensson H, Sylven C. Survival and prognostic factors in 189 dogs with dilated cardiomyopathy. J Am Anim Hosp Assoc 1997;33:364-368.
49. Calvert CA. Effect of medical therapy on survival of patients with dilated cardiomyopathy. Vet Clin North Am Small Anim Pract 1991;21:919-930.
50. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. For the PROMISE Study Research Group. N Engl J Med 1991;325:1468-1475.
51. Cowley AJ. Skene AM. Treatment of severe heart failure: Quantity or quality of life? A trial of enoximone. Br Heart J 1994;72: 226-230.
52. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure Vesnarinone Trial Investigators N Engl J Med 1998;339: 1810-1816.
53. Ewy GA. Inotropic infusions for chronic congestive heart failure: Medical miracles or misguided medicinals? J Am Coll Cardiol 1999;33:572-575.
54. Packer M. The development of positive inotropic agents for chronic heart failure: How have we gone astray? J Am Coll Cardiol 1993;22:119A-126A.
55. Asanoi H, Inoue H. Positive inotropic agents: A double-edged sword for chronic heart failure. Intern Med 1996;35 63-64.
56. Sasayama S. Inotropic agentb in the treatment of heart failure: Despair or hope? Cardiovasc Drugs Ther 1997,10:703-709.
57. Silver MA. Intermittent inotropes for advanced heart failure: Inquiring minds want to know. Am Heart J 1999;138:191-192.
58. Takaoka H, Takeuchi M, Odake M, et al. Comparison of the effects on arterial-ventricular coupling between phosphodiesterase inhibitor and dobutamine in the diseased human heart. J Am Coll Cardiol 1993;22:598-606.
59. van Meel JC, Mauz AB, Wienen W, et al. Pimobendan increases survival of cardiomyopathic hamsters. J Cardiovasc Pharmacol 1989; 13:508-509.
60. Sasaki T, Kubo T, Komamura K, Nishimi T. Effects of long-term treatment with pimobendan on neurohumoral factors in patients with non-ischemic chronic moderate heart failure. J Cardiol 1999;33: 317-325.
61. Keister DM, Kittleson MD, Bonagura JD, et al. Milrinone: A clinical trial in 29 dogs with moderate to severe congestive heart failure. J Vet Intern Med 1990;4:79-86.
62. Kittleson MD. Johnson LE. Pion PD. The acute hemodynamic effects of milrmone in dogs with severe idiopathic myocardial failure. J Vet Intern Med 1987;1:121-127.
63. Kittleson MD. The efficacy and safety of milrinone for treating heart failure in dogs. Vet Clin North Am Small Anim Pract 1991;21: 905-918.
64. Kittleson MD, Pipers FS, Knauer KW, et al. Echocardiographic and clinical effects of milrinone in dogs with myocardial failure. Am J Vet Res 1985:46:1659-1664.
65. Iwasaki A, Matsumori A, Yamada T, et at. Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis J Am Coll Cardiol 1999;33:1400-1407.
66. Calvert CA, Jacobs G, Pickus CW. Bradycardia-associated episodic weakness, syncope, and aborted sudden death in cardiomyopathic Doberman Pinschers,. J Vet Intern Med 1996;10.88-93.
67. Calvert CA, Hall G. Jacobs G, Pickus C. Clinical and pathologic findings in Doberman Pinschers with occult cardiomyopathy that died suddenly or developed congestive heart failure: 54 cases (1984-1991). J Am Vet Med Assoc 1997;210:505-511.
68. Kittleson MD, Keene B, Pion PD, et al. Results of the multicenter spaniel trial (MUST): Taurine- and carnitine-responsive dilated cardiomyopathy in American Cocker Spaniels with decreased plasma taurine concentration. J Vet Intern Med 1997;11:204-211.